Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Earnings Calls In Brief

This article was originally published in The Gray Sheet

Executive Summary

NuVasive: CEO Alexis Lukianov predicts that the firm will break even by the end of 2006 following a strong third quarter. During a Q3 conference call, Lukianov announced that the firm had raked in $15.1 mil. in revenue, up 48% from the prior-year period. After launching several spinal implants and instrument products during the quarter, the firm is developing a direct sales force to replace its distributors. NuVasive is now 30% represented by direct reps, up from 21% in Q2, and hopes to reach at least 80% by mid-2006. The firm filed an IDE for its NeoDisc cervical nucleus replacement device at the end of October, putting it on track for a 2010 launch (1"The Gray Sheet" Oct. 31, 2005, In Brief)...

Related Content

NuVasive files IDE
Encore/Empi Merger May Provide Greater-Than-Expected Cost Savings



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts